

You are cordially invited to

GAME-CHANGING NEWS ABOUT CANCER RESEARCH

A Physician Panel Presentation

Tuesday, September 27, 2016 5:30 PM | Wine and Hors D'oeuvres 6:00-7:00 PM | Program and Q&A

> Dallas Country Club Ballroom

Moderator: Rena Pederson Honorary Chairs: Marilyn Augur & Cindy Brinker Simmons

RSVP by September 21, 2016

214.658.1951 or ekuo@marycrowley.org



Margaret Jourdan



Dr. John Nemunaitis, Executive Medical Director of MCCR. Dr. Nemunaitis has been exploring novel targeted and immune therapies for cancer patients for 25 years. He trained in Hematology and Oncology at the University of Washington Fred Hutchinson Cancer Research Center in Seat-

tle, under the leadership of Nobel Laureate Donnall Thomas, MD. He established the translational research program at Mary Crowley in Dallas, conducting clinical trials since 1997. Dr. Nemunaitis has authored 337 peer-reviewed publications and 44 book chapters.



Dr. F. Charles Brunicardi, MD, PhD, FACS, MCCR Board Member. Dr. Brunicardi serves as Professor and Chief, Department of Surgery at UCLA Medical School. Prior to appointment at UCLA, he was the DeBakey/Bard Professor & Chairman at the Department of Surgery, Baylor Col-

lege of Medicine. Among numerous peer-reviewed publications, Dr. Brunicardi is editor-in-chief of the world's leading general surgery text, Schwartz's *Principles of Surgery*. His primary research areas of interest focus on personalized medicine and pancreatic/neuroendocrine cancers.



Dr. Neil Senzer, Scientific Director of MCCR. Dr. Senzer's expertise in molecular therapeutics includes proteogenomics, viral vectors and therapeutics, nanoparticle delivery, molecular immunology, molecular and systems biology, and protocol construction. He has authored 160 articles in peer-reviewed publications. Fol-

lowing internship and residency at Johns Hopkins Hospital, he completed a pediatric hematology/oncology fellowship at St. Jude's Hospital.